EXOZ — what changed in the latest 10-Q
A section-by-section comparison of EXOZ's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-13 vs the prior 10-Q · 2026-05-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +39 | −14 | ~48 | 55 |
| Market risk (Item 3) | Text added/removed | +39 | −14 | ~47 | 55 |
| Controls & procedures | Text added/removed | +39 | −14 | ~47 | 55 |
| Legal proceedings | Text added/removed | +39 | −14 | ~47 | 55 |
| Risk factors | Text added/removed | +39 | −14 | ~47 | 55 |
| Other information | Text added/removed | +39 | −14 | ~46 | 55 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice